JP7532514B2 - Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法 - Google Patents

Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法 Download PDF

Info

Publication number
JP7532514B2
JP7532514B2 JP2022523992A JP2022523992A JP7532514B2 JP 7532514 B2 JP7532514 B2 JP 7532514B2 JP 2022523992 A JP2022523992 A JP 2022523992A JP 2022523992 A JP2022523992 A JP 2022523992A JP 7532514 B2 JP7532514 B2 JP 7532514B2
Authority
JP
Japan
Prior art keywords
erbb
cancer
gene
sequence
nrg1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022523992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553104A (ja
Inventor
アーネスト・アイザック・ワッサーマン
レオナルド・アンドレス・シリュルニク
Original Assignee
メルス ナムローゼ フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルス ナムローゼ フェンノートシャップ filed Critical メルス ナムローゼ フェンノートシャップ
Publication of JP2022553104A publication Critical patent/JP2022553104A/ja
Priority to JP2024030027A priority Critical patent/JP7678175B2/ja
Application granted granted Critical
Publication of JP7532514B2 publication Critical patent/JP7532514B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022523992A 2019-10-24 2020-10-23 Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法 Active JP7532514B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024030027A JP7678175B2 (ja) 2019-10-24 2024-02-29 Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2024097 2019-10-24
NL2024097 2019-10-24
PCT/NL2020/050656 WO2021080428A1 (en) 2019-10-24 2020-10-23 Means and methods for treating subjects with her2 and her3 positive cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024030027A Division JP7678175B2 (ja) 2019-10-24 2024-02-29 Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法

Publications (2)

Publication Number Publication Date
JP2022553104A JP2022553104A (ja) 2022-12-21
JP7532514B2 true JP7532514B2 (ja) 2024-08-13

Family

ID=68807359

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523992A Active JP7532514B2 (ja) 2019-10-24 2020-10-23 Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法
JP2024030027A Active JP7678175B2 (ja) 2019-10-24 2024-02-29 Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024030027A Active JP7678175B2 (ja) 2019-10-24 2024-02-29 Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法

Country Status (9)

Country Link
US (1) US20220372166A1 (enExample)
EP (1) EP4048702A1 (enExample)
JP (2) JP7532514B2 (enExample)
KR (1) KR20220103954A (enExample)
CN (2) CN114761436A (enExample)
AU (1) AU2020371040B2 (enExample)
CA (1) CA3158609A1 (enExample)
TW (1) TWI873210B (enExample)
WO (1) WO2021080428A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058341A1 (en) * 2017-03-31 2018-10-04 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182422A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828043A1 (en) * 2011-03-15 2012-09-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
CA2870821C (en) 2012-04-20 2022-06-14 Merus B.V. Methods and means for the production of ig-like molecules
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JP6967853B2 (ja) * 2014-02-28 2021-11-17 メルス ナムローゼ フェンノートシャップ ＥｒｂＢ−２およびＥｒｂＢ−３に結合する抗体
WO2015130172A1 (en) * 2014-02-28 2015-09-03 Merus B.V. Antibodies that bind egfr and erbb3
US20210206875A1 (en) * 2017-03-31 2021-07-08 Merus N.V. Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
BR112019024230A2 (pt) * 2017-05-17 2020-06-09 Merus N.V. combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama
JP2023548375A (ja) * 2020-11-04 2023-11-16 メルス ナムローゼ フェンノートシャップ Ｅｒｂｂ３変異陽性がんを有する対象を治療するための手段及び方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182422A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Cell，2018年05月14日，Vol.33, No.5，pp.922-936

Also Published As

Publication number Publication date
US20220372166A1 (en) 2022-11-24
WO2021080428A1 (en) 2021-04-29
EP4048702A1 (en) 2022-08-31
KR20220103954A (ko) 2022-07-25
AU2020371040B2 (en) 2025-10-09
TWI873210B (zh) 2025-02-21
JP2024071393A (ja) 2024-05-24
CA3158609A1 (en) 2021-04-29
CN114761436A (zh) 2022-07-15
TW202130664A (zh) 2021-08-16
AU2020371040A1 (en) 2022-05-12
JP2022553104A (ja) 2022-12-21
CN116327919A (zh) 2023-06-27
JP7678175B2 (ja) 2025-05-15

Similar Documents

Publication Publication Date Title
US12247078B2 (en) ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
KR20160092992A (ko) 암 바이오마커 및 이의 용도
TW201642897A (zh) Ｈｅｒ２結合劑治療
US20240026029A1 (en) Means and methods for treating subjects with erbb3 mutation positive cancer
WO2018182420A1 (en) Antibodies for the treatment of erbb-2/erbb-3 positive tumors
JP7678175B2 (ja) Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法
CN118055949A (zh) 使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症
KR102905513B1 (ko) NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB-2 및 ErbB-3 결합 이중특이적 항체
WO2025188180A1 (en) Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated nrg1 expression
HK40021172A (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220621

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240731

R150 Certificate of patent or registration of utility model

Ref document number: 7532514

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150